GregoryEversonMD
Gastroenterology • Greenwood Village, COHepatology & Liver Transplantation
CEO CMO HepQuant LLC
Dr. Everson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5251 DTC Parkway
Suite 300
Greenwood Village, CO 80111Phone+1 303-923-2147- Is this information wrong?
Education & Training
University of ColoradoFellowship, Gastroenterology, 1979 - 1981
Creighton University School of Medicine (Omaha)Residency, Internal Medicine, 1976 - 1979
Weill Cornell MedicineClass of 1976
Certifications & Licensure
CO State Medical License 1979 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Gastroenterology
- American Board of Internal Medicine Transplant Hepatology
Awards, Honors, & Recognition
- Fellow of the American Society of Transplantation AST, 2010
- Fellow of the American Association for the Study of Liver Disease AASLD, 2010
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Join now to see all
Clinical Trials
- Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment Start of enrollment: 2000 Jun 01
- Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation Start of enrollment: 2005 Sep 01
- HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network Start of enrollment: 2011 Nov 01
Publications & Presentations
PubMed
- 5 citationsHepQuant SHUNT Detects Portal Hypertension in Early Stages of Clinically Compensated Chronic Liver DiseaseAmanda Wieland, Ohad Etzion, Rabab Ali, Elliot Levy, David E. Kleiner, Steve M. Helmke, Theo Heller, Gregory T. Everson> ;Clinical Gastroenterology and Hepatology. 2021 Apr 22
- Editorial: stratifying risk of adverse outcomes in cirrhosis-the Hepquant SHUNT test. Authors' reply.Sumeet K. Asrani, Gregory T. Everson> ;Alimentary Pharmacology & Therapeutics. 2021 Apr 1
- 6 citationsPredicting clinical decompensation in patients with cirrhosis using the Hepquant‐SHUNT testMohammad Amin Fallahzadeh, Daniel Hansen, James F. Trotter, Gregory T. Everson, Giovanna Saracino, Robert S. Rahimi, Steve M. Helmke, Jodi Boutte, Sumeet K. Asrani> ;Alimentary Pharmacology & Therapeutics. 2021 Feb 8
- Join now to see all
Press Mentions
HepQuant’s Disease Severity Index (DSI) Demonstrates Hepatic Functional Improvement in High Percentage of NASH Patients Treated with Obeticholic Acid: Results from INTERCEPT 747-117April 4th, 2019- HepQuant Appoints Sean Bundy Director of Regulatory & Quality AffairsAugust 2nd, 2018
2015 AST FAST DesigneesMay 21st, 2015
Professional Memberships
- Fellow
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
